top of page
News, Events and Updates
Search
Sep 21, 2022
Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders
Sep 7, 2022
Anavex Life Sciences to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022
Aug 23, 2022
Anavex Reports Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation in AD
Aug 9, 2022
Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Third Quarter Financial Results
Aug 4, 2022
Anavex Life Sciences to Participate at the BTIG Biotechnology Conference 2022
Aug 3, 2022
Anavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday, Aug. 9 2022
Aug 2, 2022
Long-lasting Effect of ANAVEX®3-71 Prevents Cognitive Decline in Animal Model of AD at AAIC 2022
Jul 31, 2022
Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
Jun 20, 2022
Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release
Jun 8, 2022
Anavex’s Publication Supports Clinical Biomarker for ANAVEX®2-73 in Fragile X Syndrome
May 19, 2022
Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022
6
7
8
9
10
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
